Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Cabaletta Bio, Inc. Common Stock (CABA)

Biological Products, (no Disgnostic Substances)

https://www.cabalettabio.com

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

2929 ARCH STREET, SUITE 600
PHILADELPHIA, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/25/2019

Market Cap

216,888,228

Shares Outstanding

42,850,000

Weighted SO

42,849,412

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

TCRR --.--%

RVMD --.--%

BDTX --.--%

BCEL --.--%

PASG --.--%

ETNB --.--%

MDGL --.--%

PLRX --.--%

Beta

2.4170

Last Div

0.0000

Range

3.471-26.35

Chg

-0.0200

Avg Vol

1289954

Mkt Cap

216888228

Exch

NASDAQ

Country

US

Phone

267 759 3100

DCF Diff

-0.0668

DCF

4.5968

Div Yield

0.0000

P/S

54.0868

EV Multiple

-0.4615

P/FV

1.1003

Div Yield %

0.0000

P/E

-2.4398

PEG

-0.3599

Payout

0.0000

Current Ratio

11.5233

Quick Ratio

11.5233

Cash Ratio

9.9789

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1019.8245

CCC

-1019.8245

Gross Margin

0.6234

Op Margin

-24.9686

Pretax Margin

-22.4397

Net Margin

-22.4397

Eff Tax Rate

-0.0161

ROA

-0.4139

ROE

-0.4398

ROCE

-0.5018

NI/EBT

1.0000

EBT/EBIT

0.8987

EBIT/Rev

-24.9686

Debt Ratio

0.0340

D/E

0.0371

LT Debt/Cap

0.0000

Total Debt/Cap

0.0358

Int Coverage

-90.8566

CF/Debt

-9.9769

Equity Multi

1.0897

Rec Turnover

0.0000

Pay Turnover

0.3579

Inv Turnover

0.0000

FA Turnover

0.4501

Asset Turnover

0.0184

OCF/Share

-1.4931

FCF/Share

-1.5302

Cash/Share

4.1101

OCF/Sales

-18.4112

FCF/OCF

1.0248

CF Coverage

-9.9769

ST Coverage

-9.9769

CapEx Coverage

-40.2997

Div&CapEx Cov

-40.2997

P/BV

1.1003

P/B

1.1003

P/S

54.0868

P/E

-2.4398

P/FCF

-2.8666

P/OCF

-2.9736

P/CF

-2.9736

PEG

-0.3599

P/S

54.0868

EV Multiple

-0.4615

P/FV

1.1003

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 14, 06:00 Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 MarketWatch Nov 28, 17:04 Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy GlobeNewswire Inc. Nov 28, 16:30 Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference Benzinga Nov 15, 12:00 Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know Benzinga Nov 10, 10:00 Where Cabaletta Bio Stands With Analysts Benzinga Oct 24, 11:00 Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023

Revenue Product Segmentation